• 1
    Palella Fj Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853 60. See comments.
  • 2
    Centers for Disease Control and Prevention. Update: trends in AIDS incidence—United States,1996. MMWR. 1997;46:861 7.
  • 3
    Centers for Disease Control and Prevention. HIV AIDS Surveillance Report. December 1998. Washington, DC: US Department of Health and Human Services; 1999.
  • 4
    Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395 401.
  • 5
    Johnson PA, Lee TH, Cook EF, Rouan GW, Goldman L. Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med. 1993;118:593 601.
  • 6
    Maynard C, Fisher LD, Passamani ER, Pullum T. Blacks in the coronary artery surgery study (CASS): race and clinical decision making. Am J Public Health. 1986;76:1446 8.
  • 7
    Todd KH. Pain assessment and ethnicity. Ann Emerg Med. 1996; 27:421 3.
  • 8
    Moore RD, Bone LR, Geller G, Mamon JA, Stokes EJ, Levine DM. Prevalence, detection, and treatment of alcoholism in hospitalized patients. JAMA. 1989;261:403 7.
  • 9
    Powe NR, Griffiths RI, De Lissovoy G, et al. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA. 1992;268:1434 40.
  • 10
    Diehr P, Yergan J, Chu J, et al. Treatment modality and quality differences for black and white breast-cancer patients treated in community hospitals. Med Care. 1989;27:942 58.
  • 11
    Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763 8.
  • 12
    Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998; 280:547 9.
  • 13
    Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544 6.
  • 14
    Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955 6. Letter.
  • 15
    Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930 7.
  • 16
    Wainberg MA & Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977 83.
  • 17
    Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307 11.
  • 18
    Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis. 1994; 169:411 5.
  • 19
    Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis. 1997;175:1502 6.
  • 20
    Donovan R, Berrey M, Corey L, Mayers D. Prevalence of Protease Inhibitor and Reverse Transcriptase Inhibitor Resistance Mutations in Recent HIV-1 Seroconverters in Seattle. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
  • 21
    Boden D, Hurley A, Zhang L, et al. Prevalence of HIV-1 drug resistance mutations in newly infected individuals remains stable over a 3 year period. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
  • 22
    Ziegelstein RC, Bush DE, Fauerbach JA. Depression, adherence behavior, and coronary disease outcomes. Arch Intern Med. 1998; 158:808 9. Letter.
  • 23
    Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88 90.
  • 24
    Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med. 1998;24:35 9.
  • 25
    Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531 3.
  • 26
    Cochrane GM. Compliance and outcomes in patients with asthma. Drugs. 1996;52:12 9.
  • 27
    Everett KD, Brantley PJ, Sletten C, Jones GN, McKnight GT. The relation of stress and depression to interdialytic weight gain in hemodialysis patients. Behav Med. 1995;21:25 30.
  • 28
    Sensky T, Leger C, Gilmour S. Psychosocial and cognitive factors associated with adherence to dietary and fluid restriction regimens by people on chronic haemodialysis. Psychother Psychosomat. 1996; 65:36 42.
  • 29
    Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261 9.
  • 30
    Patterson D, Swindells S, Mohr J, et al. How Much Adherence is Enough? A Prospective Study of Adherence to Protease Inhibitor Therapy Using MEMSCaps. Presented at the 6th Conference on Retrovirus and Opportunistic Infections, Chicago, Ill, 1999.
  • 31
    Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996;22:475 87.
  • 32
    Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med. 1997;102:164 70.
  • 33
    Caminero JA, Pavon JM, Rodriguez de Castro F, et al. Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax. 1996;51:1130 3.
  • 34
    Marco A, Cayl JA, Serra M, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J. 1998;12:967 71.
  • 35
    Tulsky J, Pilote L, Hahn J, Charlebois E, Chesney M, Moss AR. Adherence to TB prevention in the homeless. Presented at the American Thoracic Society Meeting, Chicago, Ill, 1999.
  • 36
    Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev. 1996;8:58 71.
  • 37
    Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495 502.
  • 38
    Singh N, Berman S, Swindells S, et al. Adherence to antiretroviral therapy in HIV infected patients: impact of demographic, psychosocial, and medical regimen related variables. Presented at the International Disease Society of America annual meeting, Denver, Colo, 1998.
  • 39
    Haubrich R, Little S, Dube M, et al. Self-reported treatment adherence and drug/alcohol use are associated with virologic outcomes in CCTG 570: a clinical strategy trial of HIV antiretroviral monitoring. Presented at the 12th World AIDS Conference, Geneva, Switzerland, 1998.
  • 40
    Newman RG & Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2:485 8.
  • 41
    Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969;280:1372 5.
  • 42
    Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. J Subst Abuse Treat. 1999;16:129 35.
  • 43
    Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM, Tusel DJ, Hall SM. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998;66:832 7.
  • 44
    Siqueland L, Crits-Christoph P, Frank A, et al. Predictors of dropout from psychosocial treatment of cocaine dependence. Drug Alcohol Depend. 1998;52:1 13.
  • 45
    Cantwell B & McBride AJ. Self detoxication by amphetamine dependent patients: a pilot study. Drug Alcohol Depend. 1998;49:157 63.
  • 46
    Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend. 1997;46:105 13.
  • 47
    Cameron DW H-CM, Kravick S, et al. The advanced HIV Ritonavir Study Group: prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with Ritonavir update. Presented at the 11th International Conference of AIDS. Vancouver, Canada, 1996.
  • 48
    Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278:63 5.
  • 49
    Gulick R, Mellors J, Havlir D, et al. Treatment with Indinavir (IDV), Zidovudine (ZDV), and Lamivudine (3TC): three-year follow-up. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
  • 50
    Rosenberg E. Preserving HIV-1 specific T-cell help: will it prevent progression? Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
  • 51
    Autran B. Effects of antiretroviral therapy on immune reconstitution. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999.
  • 52
    Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J. 1980;123:119 22.